In Japan, ceritinib was initially approved for crizotinib-resistant or intolerant ALK+ unresectable advanced/recurrent NSCLC (March 2016), and later received supplemental approval for ALK+ unresectable advanced/recurrent NSCLC (September 2017)3. This evidence concerns the gene ALK and non-small cell lung carcinoma.